Brief: Rhythm Pharmaceuticals Says Phase 2 Signal Trial Shows Bivamelagon Reduces BMI In Hypothalamic Obesity
12/07/2025 23:10
July 12 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O: RHYTHM PHARMACEUTICALS INC - PHASE 2 SIGNAL TRIAL SHOWS BIVAMELAGON REDUCES BMI IN HYPOTHALAMIC OBESITY RHYTHM PHARMACEUTICALS INC - PHASE 3 TRANSCEND TRIAL SHOWS SETMELANOTIDE REDUCES BMI IN HYPOTHALAMIC OBESITY Source text: ID:nGNXbDqsNv Further company coverage: RYTM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand